Genmab Completes $89M Share Buyback Program to Offset RSU Dilution

summarizeSummary

Genmab A/S announced the completion of its share buyback program, repurchasing 342,130 shares for approximately $89 million to offset dilution from its Restricted Stock Unit program.

check_boxKey Events

• Share Buyback Program Completed

  Genmab announced the completion of its share buyback program on March 13, 2026, ahead of the anticipated March 31 deadline.

• Significant Repurchase Value

  The company repurchased 342,130 shares for a total value of 615.1 million DKK (approximately $89 million USD).

• Treasury Share Holdings Updated

  Following the program, Genmab now holds 2,859,663 treasury shares, representing 4.45% of its total share capital and voting rights.

• Offsets RSU Dilution

  The buyback program was initiated to honor commitments under the company's Restricted Stock Unit (RSU) program, effectively mitigating potential dilution from employee compensation.

auto_awesomeAnalysis

This filing confirms the successful completion of Genmab's previously announced share buyback program, which aimed to repurchase shares to mitigate the dilutive effect of its Restricted Stock Unit (RSU) program. The company repurchased the full target of 342,130 shares for a total value of 615.1 million DKK (approximately $89 million USD). The completion of this program demonstrates the company's commitment to managing shareholder dilution and optimizing its capital structure. Investors should view this as a positive step in capital management.